MA30268B1 - Derive polycyclique de cinnamide - Google Patents

Derive polycyclique de cinnamide

Info

Publication number
MA30268B1
MA30268B1 MA31220A MA31220A MA30268B1 MA 30268 B1 MA30268 B1 MA 30268B1 MA 31220 A MA31220 A MA 31220A MA 31220 A MA31220 A MA 31220A MA 30268 B1 MA30268 B1 MA 30268B1
Authority
MA
Morocco
Prior art keywords
cinnamide
polycyclic derivative
novel pharmaceutical
polycyclic
derivative
Prior art date
Application number
MA31220A
Other languages
English (en)
Inventor
Teiji Kimura
Noritaka Kitazawa
Toshihiko Kaneko
Nobuaki Sato
Koki Kawano
Koichi Ito
Eriko Doi
Mamoru Takaishi
Takeo Sasaki
Takashi Doko
Takehiko Miyagawa
Hiroaki Hagiwara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA30268B1 publication Critical patent/MA30268B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

«Composition pharmaceutique nouvelle» Il est révélé des compositions pharmaceutiques nouvelles contenant de l'acide 3'-[(2Z)-[1-(3,4-diméthylphényl)-1,5-dihydro-3-méthyl-5-oxo-4H-pyrazole-4-ylidène]hydrazino]-2'-hydroxy-[1,1'-biphényl]-3-carboxylique bis-(monoéthanolamine) (eltrombopag olamine) et des procédés pour leur préparation.
MA31220A 2006-03-09 2008-09-08 Derive polycyclique de cinnamide MA30268B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78051706P 2006-03-09 2006-03-09
JP2006063562 2006-03-09
US86170206P 2006-11-30 2006-11-30
JP2006322728 2006-11-30

Publications (1)

Publication Number Publication Date
MA30268B1 true MA30268B1 (fr) 2009-03-02

Family

ID=38474999

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31220A MA30268B1 (fr) 2006-03-09 2008-09-08 Derive polycyclique de cinnamide

Country Status (15)

Country Link
EP (1) EP1992618B1 (fr)
KR (1) KR101464651B1 (fr)
AR (1) AR059955A1 (fr)
AU (1) AU2007223158B2 (fr)
CA (1) CA2643796A1 (fr)
CY (1) CY1112767T1 (fr)
EA (1) EA016464B1 (fr)
GE (1) GEP20115139B (fr)
HN (1) HN2008001374A (fr)
HR (1) HRP20120174T1 (fr)
IL (1) IL193770A (fr)
MA (1) MA30268B1 (fr)
MX (1) MX2008011221A (fr)
PL (1) PL1992618T3 (fr)
WO (1) WO2007102580A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
MY144960A (en) 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
JP2010518080A (ja) * 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
AU2008250436B2 (en) 2007-05-11 2013-03-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
EP2152695A2 (fr) * 2007-06-01 2010-02-17 Schering Corporation Modulateurs de sécrétase gamma
ES2529648T3 (es) * 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2217604A1 (fr) 2007-11-05 2010-08-18 Schering Corporation Modulateurs de gamma-secrétase
WO2009076337A1 (fr) * 2007-12-11 2009-06-18 Schering Corporation Modulateurs de la gamma sécrétase
RU2527177C2 (ru) 2007-12-20 2014-08-27 Энвиво Фармасьютикалз, Инк. Четырехзамещенные бензолы
CA2705411A1 (fr) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Derives heteroaryles en tant qu'antagonistes du recepteur a orexine
KR101244517B1 (ko) 2008-01-11 2013-03-18 에프. 호프만-라 로슈 아게 아밀로이드 베타에 대한 조절제
AU2009216851B2 (en) 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
JP2012501336A (ja) * 2008-08-27 2012-01-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の製造法
WO2010040661A1 (fr) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulateurs pour l'amyloïde bêta
CA2742317A1 (fr) * 2008-11-06 2010-05-14 Schering Corporation Modulateurs de secretase gamma
JP2012508180A (ja) * 2008-11-06 2012-04-05 シェーリング コーポレイション γ−セクレターゼ調節剤
AU2009312856A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
CA2742472A1 (fr) 2008-11-13 2010-05-20 Schering Corporation Modulateurs de gamma secretase
CA2747744A1 (fr) 2008-12-22 2010-07-01 Theodros Asberom Modulateurs de gamma secretase
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012121809A (ja) * 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
EP2401277A1 (fr) 2009-02-26 2012-01-04 Eisai R&D Management Co., Ltd. Sel de dérivé de tétrahydrotriazolopyridine et ses cristaux
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
TW201035101A (en) * 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
US20120142672A1 (en) 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
US8871760B2 (en) * 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
AU2011206635B2 (en) * 2010-01-15 2015-01-22 Cellzome Limited Novel substituted triazole derivatives as gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8513230B2 (en) 2010-03-05 2013-08-20 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2611805A1 (fr) 2010-09-02 2013-07-10 Takeda Pharmaceutical Company Limited Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger
JP2014012641A (ja) * 2010-10-29 2014-01-23 Dainippon Sumitomo Pharma Co Ltd 新規ピリジン誘導体
CN103402359B (zh) * 2011-01-17 2016-08-24 卡尔约药物治疗公司 含烯烃核运输调节剂及其用途
EP2736887B1 (fr) 2011-07-29 2017-10-18 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire contenant de l'hydrazide et leurs utilisations
EP2736883B1 (fr) 2011-07-29 2019-09-04 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
WO2013055793A1 (fr) 2011-10-12 2013-04-18 University Of Pittsburg-Of The Commonwealth System Of Higher Education Petites molécules ciblant la localisation et/ou le niveau nucléaire des récepteurs de l'androgène dans le cancer de la prostate
IN2014DN09434A (fr) 2012-05-09 2015-07-17 Karyopharm Therapeutics Inc
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
EP2687528A1 (fr) * 2012-07-17 2014-01-22 Ares Trading S.A. Dérivés de triazole fusionnés comme modulateurs de gamma-sécrétase
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
WO2014144772A1 (fr) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Procédés de promotion de la cicatrisation d'une plaie à l'aide d'inhibiteurs de crm1
CN110386919B (zh) 2013-06-21 2023-07-14 卡尔约药物治疗公司 核转运调节剂及其用途
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
EP3046561B1 (fr) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Composés destinés au traitement du cancer de la prostate
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
EP3397634A1 (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Modulateurs de transport nucléaire et leurs utilisations
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
PL3419979T3 (pl) * 2016-02-23 2020-06-29 Pfizer Inc. Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288898T1 (de) * 2000-12-04 2005-02-15 Hoffmann La Roche Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
BRPI0511504A (pt) * 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides

Also Published As

Publication number Publication date
GEP20115139B (en) 2011-01-10
EA016464B1 (ru) 2012-05-30
HK1122027A1 (en) 2009-05-08
HRP20120174T1 (hr) 2012-03-31
CA2643796A1 (fr) 2007-09-13
HK1128085A1 (en) 2009-10-16
EP1992618B1 (fr) 2012-01-18
IL193770A0 (en) 2009-05-04
PL1992618T3 (pl) 2012-06-29
CY1112767T1 (el) 2016-02-10
KR20080108481A (ko) 2008-12-15
IL193770A (en) 2012-10-31
KR101464651B1 (ko) 2014-11-24
WO2007102580A1 (fr) 2007-09-13
MX2008011221A (es) 2008-09-11
EP1992618A4 (fr) 2010-11-10
AU2007223158B2 (en) 2012-04-12
AR059955A1 (es) 2008-05-14
HN2008001374A (es) 2011-03-15
EA200870336A1 (ru) 2009-02-27
AU2007223158A1 (en) 2007-09-13
EP1992618A1 (fr) 2008-11-19

Similar Documents

Publication Publication Date Title
ECSP077628A (es) Nueva composición farmacéutica
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA34013B1 (fr) Inhibiteurs du virus de l'hépatite c
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
CR9314A (es) Derivado de espirocetal y uso del mismo como medicina para la diabetes
MA29746B1 (fr) Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
MA29791B1 (fr) Composes therapeutiques.
MA30526B1 (fr) Inhibiteurs de prolyle hydroxylase
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
TN2009000138A1 (fr) Biaryl-ether-urees
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.
MA30487B1 (fr) Nouveaux composes heterocycliques
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA34308B1 (fr) Triazolopyridines substituées
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
TNSN07366A1 (fr) Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie
DE60122555D1 (de) Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
EP2202222A3 (fr) Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
EP3395805A1 (fr) Composés présentant une activité antitumorale, anti-infectieuse et antimycosique